Zhejiang Bossan Pharma out-licensed global ex-China rights for its innovative novel epidermal growth factor receptor (EGFR) inhibitor to CBT Pharma of California. CBT plans to test two of its own candidates — a c-Met inhibitor and an anti-PD1 antibody — together with the Bossan EGFR inhibitor, which is currently in a Phase I China trial. CBT has already partnered China rights for the c-Met inhibitor to Beijing Pearl Biotech and the anti-PD1 antibody to Genor Biotech.
Source: China Biotoday
